Kinarus Therapeutics to host KOL event on Monday, June 27, to discuss therapies in wet Age-Related Macular Degeneration and potential advantages of KIN001
Kinarus has received regulatory authorization to initiate Phase 2 testing of KIN001 to treat wet age-related macular degeneration (wAMD) as communicated previously on May 10, 2022.
- Kinarus has received regulatory authorization to initiate Phase 2 testing of KIN001 to treat wet age-related macular degeneration (wAMD) as communicated previously on May 10, 2022.
- KIN001 has been shown to reduce pathological blood vessel growth (neovascularization) in the choroid of the eye in preclinical models of wAMD.
- Kinarus CEO Alexander Bausch will present the KIN001 development plans in wAMD and other indications.
- Investors can request to attend the KOL event in person or participate in the live video webcast of the KOL event.